Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Transitional Cell

Explore clinical trials studying Carcinoma, Transitional Cell. Study availability and eligibility vary by location and protocol.

417 public trials 125 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Transitional Cell trial results

Active, Not Recruiting

JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

NCT06412848

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +3 more
Locations
  • Hirosaki University Hospital Hirosaki, Aomori, Japan
  • Ehime University Hospital Tōon, Ehime, Japan
  • Kurume University Hospital Kurume, Fukuoka, Japan
  • Hokkaido University Hospital Sapporo, Hokkaido, Japan
View all 26 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04963153

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +36 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details
Active, Not Recruiting

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

NCT03047213

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +18 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 20 locations
View Trial Details
Active, Not Recruiting

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

NCT04152499

Conditions
Adnexal Diseases, Breast Cancer, Breast Diseases, +48 more
Locations
  • Los Angeles Hematology Oncology Medical Group Glendale, California, United States
  • University of California Los Angeles Los Angeles, California, United States
  • Florida Cancer Specialists and Research Institute Sarasota, Florida, United States
  • START MidWest Grand Rapids, Michigan, United States
View all 109 locations
View Trial Details
Active, Not Recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +16 more
Locations
  • Arizona Urology Specialists Tucson, Arizona, United States
  • Loma Linda University Medical Center Loma Linda, California, United States
  • Genesis Research San Diego, California, United States
  • Wichita Urology Group Wichita, Kansas, United States
View all 65 locations
View Trial Details
Active, Not Recruiting

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

NCT05661955

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +26 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • The Second Hospital and Clinical Medical School, Lanzhou University Lanzhou, Gansu, China
  • Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong, China
View all 18 locations
View Trial Details

Related conditions